Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Lori Goldstein

Email
Center AffiliationsMolecular Therapeutics

Publications (101) (print view)

no pagination
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbe JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS, Poems S Investigators. Goserelin for Ovarian Protection During Breast-Cancer Adjuvant Chemotherapy. Obstetrical & Gynecological Survey. 2015 Jun;70(6):392-3.
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. The New England journal of medicine. 2015 Mar 05;372(10):923-32.   PMCID: 4405231
Shaikh T, Tam TY, Li T, Hayes SB, Goldstein L, Bleicher R, Boraas M, Sigurdson E, Ryan PD, Anderson P. Multifocal and multicentric breast cancer is associated with increased local recurrence regardless of surgery type. Breast J. 2015 Mar;21(2):121-6.
Shaikh T, Tam TY, Li T, Hayes SB, Goldstein L, Bleicher R, Boraas M, Sigurdson E, Ryan PD, Anderson P. Multifocal and multicentric breast cancer is associated with increased local recurrence regardless of surgery type. Breast Journal. 2015 Jan;21(2):121-6.
Shih J, Bashir B, Gustafson KS, Andrake M, Dunbrack RL, Goldstein LJ, Boumber Y. Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary. J Natl Compr Canc Netw. 2015 Aug;13(8):947-52.   PMCID: 4763101
Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, Carlson RW, Chang PJ, Sparano JA, Head B, Goldstein LJ, Haley B, Dakhil SR, Reid JE, Hartman AR, Manola J, Ford JM. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. J Clin Oncol. 2015 Apr 06;33(17):1895-901.   PMCID: 4451172
Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol. 2015 Feb;33(4):340-8.   PMCID: Pmc4302215
Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology. 2014 Sep;32(27):2959-66.   PMCID: 4162494
Cole M, Parajuli S, Laske D, Goldstein L, Morrison T, Mukherjee A, Tumelty K, Tetzlaff E, von Mehren M, Inniss S. Peripheral primitive neuroectodermal tumor of the dura in a 51-year-old woman following intensive treatment for breast cancer. Am J Case Rep. 2014 Jan;15:294-9.   PMCID: Pmc4102603
Freedman GM, Fowble BL, Li T, Hwang ES, Schechter N, Devarajan K, Anderson PR, Sigurdson ER, Goldstein LJ, Bleicher RJ. Risk of positive nonsentinel nodes in women with 1-2 positive sentinel nodes related to age and molecular subtype approximated by receptor status. Breast J. 2014 Jul;20(4):358-63.   PMCID: 4472437
Goldstein LJ, Gurtler J, Del Prete SA, Tjulandin S, Semiglazov VF, Bayever E, Michiels B. Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens. Clinical Breast Cancer. 2014 Dec;14(6):396-404.
Goldstein LJ, Miller BJ, Nicotera N, Pendleton D. Reducing the time from initial call to first appointment: the impact of patient access redesign and a nurse navigation program. J Natl Compr Canc Netw. 2014 Feb;12 Suppl 1:S16-8.   PMCID: No NIH funds
Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R, Nccn. Breast Cancer Version 3.2014 Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2014 Apr;12(4):542-90.   PMCID: No NIH funds
Matro JM, Goldstein LJ. How Do I Follow Patients With Early Breast Cancer After Completing Adjuvant Therapy. Current treatment options in oncology. 2014 Mar;15(1):63-78.   PMCID: No NIH funds
Silverman D, Ruth K, Sigurdson ER, Egleston BL, Goldstein LJ, Wong YN, Boraas M, Bleicher RJ. Skin involvement and breast cancer: are T4b lesions of all sizes created equal?. Journal of the American College of Surgeons. 2014 Sep;219(3):534-44.   PMCID: Pmc4143438
Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy Little Evidence of Improvement Over the Past 30 Years. Cancer. 2013 Mar;119(6):1140-8.   PMCID: PMC3593800
Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast Cancer, Version 3.2013 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2013 Jul;11(7):753-61.   PMCID: No NIH funds
Freedman GM, Anderson PR, Bleicher RJ, Litwin S, Li TY, Swaby RF, Ma CM, Li JS, Sigurdson ER, Watkins-Bruner D, Morrow M, Goldstein LJ. Five-year Local Control in a Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy With an Incorporated Boost for Early Stage Breast Cancer. International Journal of Radiation Oncology Biology Physics. 2012 Nov;84(4):888-93.   PMCID: PMC3419789
Freedman GM, Li TY, Polli LV, Anderson PR, Bleicher RJ, Sigurdson E, Swaby R, Dushkin H, Patchefsky A, Goldstein L. Lymphatic Space Invasion is Not an Independent Predictor of Outcomes in Early Stage Breast Cancer Treated by Breast-Conserving Surgery and Radiation. Breast Journal. 2012 Sep;18(5):415-9.
Li L, Li T, Cohen RJ, Anderson PR, Goldstein LJ, Bleicher RJ, Freedman GM. Identifying patients who may be candidates for a clinical trial of salvage accelerated partial breast irradiation after previous whole breast irradiation. Int J Breast Cancer. 2012 Jan;2012:937658.   PMCID: PMC3518959
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Lori Goldstein Sparkline Graph

Graph Interactions

Co-Authors:

Similar Investigators:


Keywords (MeSH):


Last updated on Friday, December 06, 2019